Description
SACUBITRIL/VALSARTAN is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
Additional information
| brand | Ccl |
|---|
SACUBITRIL/VALSARTAN is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
| brand | Ccl |
|---|
